ACTIVE TRANSITION // NODE #04
Chief Scientific Officer Handover
Acme BioSystems Discovery Division • Aman Kumar → Marcus Vance
STATUS: CALCULATINGREADINESS: 0%
OUTGOING AUTHORITY:Aman KumarRelinquishing IND Filings & Trial Protocol Sign-Off
INCOMING SUCCESSOR:Marcus VanceIncoming Head of Translational Oncology
IMMINENT BLOCKER:Loading blockers...Synchronizing ledger...
DEPOSITED RECORDS
0 DOCS
Charters, MSAs, minutes
INDEXED TRIPLES
0 ENTITIES
100% citation linked
OPEN ANOMALIES
0 FLAGGED
Requires Switch review
READINESS SCORE
0% READY
Continuity threshold
CONTINUITY VULNERABILITY INDEX:TARGET ≥ 80% (CURRENT: 0%)
Critical Unresolved Matters & Discrepancies
Anomalies requiring human adjudication at the Switch review desk
CASE-BIO-09
Conflicting EvidenceFDA Form 1572 Principal Investigator Sign-Off Mismatch
Vendor MSA Amendment 3 names Dr. Marcus Thorne as sponsor representative, while FDA Form 1572 lists Dr. Eleanor Vance. Discrepancy risks clinical hold on Phase II Oncology trials.
SOURCE: Regulatory-Audit-Q3-2024.pdf (p. 14)Resolve in Switch →
CASE-BIO-14
Missing Record$140,000 Spectrometry Lab Contract Auto-Renewal
Automatic 12-month renewal triggers on November 15, 2024 unless written opt-out is delivered by October 15. Sign-off authority is unassigned in the transition charter.
SOURCE: Vendor-Master-Agreement-2023.docx (Sec. 8.2)Resolve in Switch →
Quick Ingestion Dock
Deposit Institutional Records
Select or drag PDF, DOCX, TXT archives • Max 25MB per file
CONTINUITY MODULES
Workspace Navigation
• Local SQLite database (WAL)
• Direct SHA-256 integrity verification